Genzyme Initiates Campath Phase III Study In Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.